Home›Trial›NCT06285318
🔬NCT06285318RECRUITING

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Study Summary

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions / Drugs
TeclistamabTalquetamab
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment900 participants
Primary Completion—
Lead SponsorJanssen-Cilag Ltd.
Data Retrieved2026-04-11 02:55:31.550369+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.